Previous 10 | Next 10 |
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research ser...
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy a...
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021. The Company h...
NeoGenomics (NEO) is trading marginally lower in the pre-market after announcing an agreement to acquire Trapelo Health (also known as Intervention Insights), an Information Technology company focused on precision oncology.The transaction expected to close in April 2021 subject to the fu...
Clinical Decision Support to Enable Precision Oncology FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acqui...
Since I last covered the stock, NeoGenomics - a cancer testing provider - has seen shares grow by 87%, to $50 at the time of writing. The company's core operations suffered in 2020 owing to the pandemic, but revenue losses were compensated by a side-line in PCR COVID testing. The ...
Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumo r Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels FORT MYERS, FL and NEW YORK, NY / ACCESSWIRE / March 16, 2021 / NeoGenomics, Inc. (NASDAQ:...
Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 ...
FT. MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chief Financial Officer Kathryn McKenzie and Doug Brown, Chief Strategy and Corpor...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: NeoGenomics, Inc. 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...